Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-15T13:56:52.677Z Has data issue: false hasContentIssue false
  • English
  • Français

Cognitive outcomes of Bergamot Polyphenolic Fraction (BPF) supplementation in schizophrenia: Preliminary data

Published online by Cambridge University Press:  23 March 2020

M. Crucitti ,
A. Bruno ,
G. Pandolfo ,
G.M. Troili ,
R.A. Zoccali  and
M.R.A. Muscatello
A. Bruno
Affiliation:
University of Messina, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina, Italy
G. Pandolfo
Affiliation:
University of Messina, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina, Italy
G.M. Troili
Affiliation:
University of Messina, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina, Italy
R.A. Zoccali
Affiliation:
University of Messina, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina, Italy
M.R.A. Muscatello
Affiliation:
University of Messina, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Cognitive deficits in schizophrenia significantly affect illness and community outcomes, and quality of life. Several studies support the neuroprotective properties of polyphenolic compounds resulting in neuronal protection, suppression of neuroinflammation and the potential to promote memory, learning and cognitive functions. Bergamot differs from other citrus fruits for flavonoids and flavonoid glycosides composition (neoeriocitrin, neohesperidin, naringin, rutin, neodesmina, roifolina and poncirina), and for their high amount. For these features, BPF may represent a potential supplement for improving cognitive functions.

Aims

The present study was aimed to explore the efficacy of BPF supplementation on clinical symptoms andcognitive functioning in a sample of schizophrenic subjects receiving atypical antipsychotics (APs).

Methods

Ten schizophrenic outpatients treated with atypical APs assumed BPF at the oral daily dose of 1000 mg/day for 30 days. Brief Psychiatric Rating Scale, Wisconsin Card Sorting Test, Verbal Fluency Task-Controlled Oral Word Association Test, and Stroop Color-Word Test were administered.

Results

The results obtained indicate that BPF administration substantially improved WCST performances (perseverative responses, P = 0.008; perseverative errors, P = 0.012; total errors, P = 0.011; categories, P = 0.023). Moreover, a trend for others clinical (BPRS) and cognitive variables (Verbal Fluency Task-Controlled Oral Word Association Test, and Stroop Color-Word Test) decrease was observed.

Conclusions

The findings provide evidence that BPF administration may be proposed as an effective therapeutic strategy to improve cognitive outcome in schizophrenia. Further clinical trials with adequately powered and well-designed methodology are needed to better explore the BPF effectiveness on cognitive impairments in schizophrenic patients.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster walk: Schizophrenia and other psychotic disorders–part 1
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S189
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.